NCT07473570RecruitingPhase 1
A Phase I Clinical Study of GS3-007a Dry Suspensions in Healthy Chinese Adults: Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Dose-Escalation, and Food Effect Study
Changchun GeneScience Pharmaceutical Co., Ltd.1 site in 1 country32 target enrollmentStarted: January 7, 2026Last updated:
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 32
- Locations
- 1
- Primary Endpoint
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Study Overview
Brief Summary
This study consists of two parts: the first part is a single-dose escalating（SAD） and food effect （FE）study, and the second part is a multiple-dose (14-day) escalating(MAD) study. Both phases are designed as randomized, double-blind, dose-escalation, placebo-controlled clinical studies.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age 18-45 years (inclusive), healthy adult subjects, both male and female are eligible;
- •Body Mass Index (BMI): 19-26 kg/m² (inclusive), males weighing ≥50 kg, females weighing ≥45 kg;
- •Fully understand the purpose, nature, and methods of the trial, as well as possible adverse reactions, voluntarily participate as subjects, sign the informed consent form (ICF) before any study procedures;
- •From screening day to 3 months after the last dose, have no plans for conception or sperm/egg donation, and agree to use reliable non-drug contraception during the trial (such as complete abstinence, intrauterine device, partner sterilization, etc.).
Exclusion Criteria
- •A highly allergic constitution
- •Individuals with a clear history of neurological or psychiatric disorders; those lacking behavioral or cognitive function.
- •Electrocardiogram (ECG) QTcF interval abnormal, with a history of QT/QTc interval prolonged; abnormal liver function; abnormal findings in physical examination, laboratory tests, or other examinations with clinical significance.
- •Individuals with a history of hepatitis B, hepatitis C, syphilis, AIDS, or with one or more clinically significant abnormal findings in infectious disease screening.
- •Individuals who are alcoholics or who regularly consumed alcohol within 6 months before the first dose of the trial, or those unwilling to stop drinking or consuming any alcohol-containing products during the entire trial.
- •Individuals with a history of heavy smoking or those who smoked an average of ≥5 cigarettes per day within the 3 months before screening
- •Individuals with immune deficiencies or immunosuppressive diseases, malignant tumors, chronic cardiovascular, liver, kidney, endocrine, respiratory, hematological (including coagulation), or digestive system diseases.
- •Individuals who underwent major surgery within 6 months before screening or during the screening period, or those who experienced acute neurological, digestive, respiratory, circulatory, endocrine, or hematological diseases within 3 months before screening;
- •Subjects who have donated blood (including blood components) within 3 months prior to the first dose, or have experienced blood loss ≥ 400 mL within 3 months prior to the first dose
- •Subjects who have participated in any clinical trial and used investigational drugs, vaccines, or devices within 3 months prior to screening
- •Subjects who have started a significantly abnormal diet within 4 weeks prior to screening or during the screening period, or have special dietary requirements, cannot comply with the standardized diet, or cannot tolerate the high-fat, high-calorie meal in postprandial trials
- •Female subjects who are pregnant or breastfeeding
Arms & Interventions
Placebo (SAD/FE)
Placebo Comparator
Intervention: Placebo GS3-007a for Suspension (Drug)
GS3-007a- dose level 1 (MAD)
Experimental
Intervention: GS3-007a for Suspension (Drug)
GS3-007a- dose level 1 (SAD/FE)
Experimental
Intervention: GS3-007a for Suspension (Drug)
GS3-007a- dose level 2 (SAD/FE)
Experimental
Intervention: GS3-007a for Suspension (Drug)
GS3-007a- dose level 2 (MAD)
Experimental
Intervention: GS3-007a for Suspension (Drug)
Placebo (MAD)
Placebo Comparator
Intervention: Placebo GS3-007a for Suspension (Drug)
Outcomes
Primary Outcomes
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time Frame: up to 6 days (SAD+FE phase), up to 21 days (MAD)
Secondary Outcomes
- Pharmacokinetics (PK) Indicators - Maximum Observed Concentration (Cmax)(up to 6 days (SAD+FE phase))
- Pharmacokinetics (PK) Indicators - Time to Reach Maximum Observed Concentration (Tmax)(up to 6 days (SAD+FE phase))
- Pharmacokinetics (PK) Indicators - Area Under the Concentration-Time Curve from Time Zero to Time t (AUC0-t)(up to 6 days (SAD+FE phase))
- Pharmacokinetics (PK) Indicators - Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC0-∞)(up to 6 days (SAD+FE phase))
- Pharmacokinetics (PK) Indicators - Time to Reach Maximum Observed Concentration at Steady State (Tss,max)(up to 21 days (MAD))
- Pharmacokinetics (PK) Indicators - Maximum Observed Concentration at Steady State (Css,max)(up to 21 days (MAD))
- Pharmacokinetics (PK) Indicators - Minimum Observed Concentration at Steady State (Css,min)(up to 21 days (MAD))
- Pharmacokinetics (PK) Indicators - Average Observed Concentration at Steady State (Css,av)(up to 21 days (MAD))
- Pharmacodynamics(PD) Indicators(up to 6 days (SAD+FE phase), up to 21 days (MAD))
- PD Indicators(The entire MAD research phase)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationsNCT07361237Tongji University36
Not yet recruiting
Not Applicable
Safety and Preliminary Efficacy of Hibernation-Like Therapy (Chlorpromazine and Promethazine) in Patients With Acute Ischemic Stroke (AIS) Eligible for Reperfusion Therapy.NCT07364344Ji Xunming,MD,PhD57
Recruiting
Phase 1
A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult ParticipantsNCT07433179Septerna, Inc.150
Recruiting
Phase 1
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSCNCT07355972Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12
Recruiting
Phase 2
A phase 2, single arm, open label, study on the safety and feasibility of Liver Isolated Oxaliplatin (LIOX) delivered via arterial access device for treatment of liver metastasis in colorectal cancer patientscolorectal cancer2025-523261-25-00UZ Leuven13